What Is Semaglutide?
Semaglutide is a GLP-1 receptor agonist — a weekly injection that mimics a natural gut hormone to reduce appetite, slow digestion, and improve insulin sensitivity. Originally FDA-approved for type 2 diabetes as Ozempic, it's now widely prescribed for weight loss under the brand name Wegovy.
Men on testosterone replacement therapy often add semaglutide to optimize body composition. Low testosterone frequently coincides with obesity, and semaglutide addresses that metabolic dysfunction directly. You inject once weekly at home, escalating the dose gradually over 16-20 weeks.
Brand versions cost $1,000-1,500 monthly without insurance. Compounded semaglutide — a pharmacy-made version using the same active ingredient — runs $300-500 monthly and has become the primary access point for men seeking weight management alongside TRT.
Semaglutide at a Glance
Semaglutide is a weekly GLP-1 injection that reduces appetite, slows digestion, and improves insulin sensitivity. Originally approved for diabetes, it's now widely used for weight loss in men optimizing body composition on TRT.
Compounded versions at $300-500 monthly have made it accessible beyond the $1,500 brand pricing.
- Mechanism: Activates GLP-1 receptors to suppress hunger and regulate glucose
- Dosing: Start 0.25 mg weekly, escalate to 1-2.4 mg over 16-20 weeks
- Safety: Nausea common; avoid if thyroid cancer history present
- Cost: $300-500/month compounded, $1,000-1,500/month brand
How Semaglutide Works
Semaglutide binds to GLP-1 receptors in your pancreas, gut, and brain.1 In the pancreas, it triggers insulin release only when blood sugar is elevated — reducing hypoglycemia risk compared to older diabetes drugs. Simultaneously, it suppresses glucagon, the hormone that raises blood sugar.
In your gut, semaglutide slows gastric emptying.2 Food stays in your stomach longer, extending the feeling of fullness after meals. That delayed emptying also blunts the post-meal glucose spike.
The appetite suppression happens centrally. GLP-1 receptors in your hypothalamus regulate hunger signaling, and semaglutide activation reduces cravings at a neurological level.1
Why Once-Weekly Dosing Works
Two structural modifications give semaglutide its 7-day half-life.3 First, an amino acid swap prevents breakdown by DPP-4, the enzyme that degrades natural GLP-1 within minutes. Second, a fatty acid chain attaches semaglutide to albumin in your bloodstream, slowing clearance.
You reach steady-state levels after 4-5 weeks of weekly injections.2 That's when the full appetite-suppressing effect kicks in. Early weeks involve dose escalation to minimize nausea — you're not at therapeutic levels yet.
Clinical Trial Results
In obesity trials, semaglutide 2.4 mg weekly produced 15% average weight loss over 68 weeks.1 For a 220-pound man, that's 33 pounds. Roughly one-third of participants lost 20% or more of their starting weight.
Head-to-head against liraglutide (a daily GLP-1 injection), semaglutide delivered superior weight reduction and better A1C control in diabetes patients.1 The weekly schedule also improved adherence.
Glucagon is a hormone produced by the pancreas that raises blood sugar levels by signaling the liver to release stored glucose into the bloodstream, opposing insulin's blood-sugar-lowering effects.
Gastric Emptying refers to the process by which food moves from the stomach into the small intestine; slowing this process extends digestion and promotes satiety.
Dosing & Administration Protocol
You start at 0.25 mg weekly for four weeks, then escalate every four weeks until you hit your target dose. Most men on TRT stop at 1 mg or 2 mg weekly depending on weight loss goals and side effect tolerance. The 2.4 mg dose is Wegovy's FDA-approved obesity dosing.
Inject subcutaneously — typically in your abdomen, thigh, or upper arm. Rotate sites to prevent lipodystrophy. Timing doesn't matter as long as you inject the same day each week. If you miss a dose by more than five days, restart at the previous lower dose to avoid severe nausea.
| Parameter | Standard Protocol | Clinical Notes |
|---|---|---|
| Starting Dose | 0.25 mg weekly × 4 weeks | Tolerance-building phase; minimal appetite suppression expected |
| Escalation | Increase by 0.25-0.5 mg every 4 weeks | Typical sequence: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg |
| Maintenance Dose | 1.0-2.4 mg weekly | Many men plateau at 1 mg; 2.4 mg reserved for obesity indication |
| Lab Monitoring | Lipid panel, liver function every 3-6 months | Watch for pancreatitis markers if abdominal pain develops |
| Injection Site | Abdomen, thigh, or upper arm | Rotate sites weekly; use a different location each injection |
Side Effects & Safety Profile
Gastrointestinal symptoms dominate the side effect profile. Nausea affects roughly half of users during dose escalation but typically improves with time. Eating smaller, more frequent meals reduces severity.
| Frequency | Side Effect | Management Strategy |
|---|---|---|
| Common (>10%) | Nausea, vomiting, diarrhea | Eat smaller meals, avoid high-fat foods, stay hydrated |
| Common (>10%) | Injection site reactions | Rotate sites, use proper technique, apply ice if needed |
| Occasional (1-10%) | Constipation, headache, fatigue | Increase fiber intake, monitor hydration |
| Occasional (1-10%) | Dizziness, abdominal pain | Usually transient; contact provider if persistent |
| Rare (<1%) | Pancreatitis, gallbladder disease | Seek immediate care for severe abdominal pain |
| Rare (<1%) | Thyroid C-cell tumors (animal studies) | Contraindicated with personal/family history of medullary thyroid cancer |
When to Stop Treatment
Discontinue immediately if you develop severe abdominal pain radiating to your back — a potential sign of pancreatitis. Also stop if you experience persistent vomiting that prevents hydration, vision changes, or signs of gallbladder inflammation (right upper quadrant pain, fever, jaundice).
Cost & Access Options
Brand-name Wegovy costs $1,300-1,500 monthly without insurance. Ozempic (the diabetes formulation) runs slightly less at $900-1,000 monthly. Insurance coverage varies wildly — most plans cover Ozempic for diabetes but deny Wegovy for weight loss unless you meet strict BMI thresholds.
Compounded semaglutide has become the primary access point. Licensed compounding pharmacies produce semaglutide using the same active pharmaceutical ingredient, typically charging $300-500 monthly. This pricing puts it within reach for men adding weight management to their TRT protocol.
Where to Get It
TRT telehealth clinics increasingly offer semaglutide as part of comprehensive metabolic optimization programs. You'll need baseline labs (lipid panel, liver function, A1C if diabetic) and a prescribing consultation. Most clinics ship compounded semaglutide with needles and alcohol wipes included.
Traditional endocrinologists prescribe brand formulations but often require documented obesity (BMI ≥30) or overweight status with comorbidities (BMI ≥27 plus hypertension or dyslipidemia). Approval timelines vary by insurance carrier.